MolecularHealth Collaborates with SAP to Offer Innovative Employer Oncology Program

THE WOODLANDS, TX, UNITED STATES - Jun 5, 2014 -  

MolecularHealth announced today the official launch of MolecularHealth™ COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP™. COPE enables self-funded employers to offer access to TreatmentMAP to their employees via a pre-packaged offering, which includes materials for employees, as well as working closely with patients’ physicians through the process of testing, analyzing and receiving results. SAP is working with MolecularHealth to become one of the first organizations to provide its employees with access to COPE and plans to offer it in the third quarter of 2014.

SAP technology also plays a role in enabling COPE; the SAP® Genomic Analyzer solution running on the SAP HANA® platform is used in an early adoption phase to speed up the genome alignment process by a factor of 300 compared to previously used algorithms.

TreatmentMAP generates an individual tumor analysis for each patient and then provides a clinical interpretation of the genomic patient data to support the patient’s physician in making an individualized treatment decision. Based on a proprietary analytics engine, TreatmentMAP leverages the results of next generation sequencing (NGS) genetic testing. Now, for the first time and in a clear and understandable way, physicians and individuals diagnosed with cancer will have access to actionable information to guide the selection of cancer treatments.

“With the advent of information-based molecular-genetic diagnosis, cancer can be individually and precisely profiled, and potentially transformed from a terminal to a chronic disease - supporting both the employee and his or her organization during the challenge of working and living with cancer,” said Dr. Friedrich von Bohlen, chairman of MolecularHealth.

The TreatmentMAP offering, available from MolecularHealth offices in the United States and in Europe, is accessible to all patients diagnosed with solid tumor cancer, regardless of where they live.

In the U.S., a patient’s oncologist or pathologist sends a tumor sample to MolecularHealth’s CLIA (Clinical Laboratory Improvement Amendments)-certified next generation sequencing lab in The Woodlands, Texas. In Europe, a patient’s treating physician works with a MolecularHealth-certified oncologist and a tumor sample is sent to a certified next generation sequencing laboratory. For sequence data generation in Europe, MolecularHealth partners with GATC Biotech, Europe’s leading service provider of Sanger and next generation sequencing, as a preferred supplier.

Once sequenced, MolecularHealth’s TreatmentMAP delivers the information necessary to provide a result report that clearly identifies treatment options, along with biomarker information, safety and efficacy data by treatment, and possible clinical trials for which the patient may be eligible. TreatmentMAP became commercially available in Europe and the U.S. in April 2014.

As noted by Dr. Werner Eberhardt, chief health platform expert at SAP AG, “Improving people’s lives is part of our mission. We are proud to be able to spearhead the use of genomic information for precision cancer treatments together with MolecularHealth with the COPE program. COPE’s early adoption use of SAP HANA helps to shorten the time from diagnosis to treatment and helps enable researchers to gain insights from connecting data from different sources. We look forward to offering this solution to our employees.”

For more information on how your company can work with MolecularHealth, please contact MolecularHealth in the U.S. or in Europe.

ABOUT MOLECULARHEALTH

MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.

In the U.S., TreatmentMAP™ is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.

MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.

Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.

Please visit www.molecularhealth.com for more information and follow on Twitter atwww.twitter.com/molecularhealth.

Website: www.molecularhealth.com
Twitter: www.twitter.com/molecularhealth
LinkedIn: www.linkedin.com/company/molecularhealth
YouTube: www.youtube.com/user/MolecularHealthInc

TreatmentMAP and all MolecularHealth logos are trademarks of MolecularHealth GmbH. SAP, SAP HANA and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries. All other product and service names mentioned are the trademarks of their respective companies.

SAP Forward-looking Statement

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

Contacts

MolecularHealth
Contact for U.S.
Gregory FCA
Jessica Attanasio
Associate Vice President
610-228-2112
Jessica@GregoryFCA.com

or

Contact for EU:
Haas & Health Partner Public Relations GmbH
Dr. Tim Jacobs
Telefon: +49.6123.7057.32
Fax: +49.6123.7057.57
jacobs@haas-health.de

# # #